{
  "id": "5509b6d22e93f0133a000005",
  "type": "summary",
  "question": "What are the treatments of choice for GIST (gastrointestinal stromal tumor)?",
  "ideal_answer": "The surgical resection is a treatment of choice for gastrointestinal stromal tumors. It has been shown that adequate surgical resection correlates with high 5-years survival rates for patients with gastric GIST.  When they are localized, the treatment of choice is surgical excision, but advanced tumors have a limited response to chemo or radiotherapy. Imatinib (STI571 or Glivec) is a selective inhibitor or tyrosine kinase proteins that has been used successfully in the treatment of advanced GIST.  ",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/16857109",
    "http://www.ncbi.nlm.nih.gov/pubmed/19097381",
    "http://www.ncbi.nlm.nih.gov/pubmed/18958964",
    "http://www.ncbi.nlm.nih.gov/pubmed/15508453",
    "http://www.ncbi.nlm.nih.gov/pubmed/16739060",
    "http://www.ncbi.nlm.nih.gov/pubmed/15655606",
    "http://www.ncbi.nlm.nih.gov/pubmed/12394270",
    "http://www.ncbi.nlm.nih.gov/pubmed/16566359",
    "http://www.ncbi.nlm.nih.gov/pubmed/15672765",
    "http://www.ncbi.nlm.nih.gov/pubmed/22678007",
    "http://www.ncbi.nlm.nih.gov/pubmed/15221987",
    "http://www.ncbi.nlm.nih.gov/pubmed/17229322",
    "http://www.ncbi.nlm.nih.gov/pubmed/16136600",
    "http://www.ncbi.nlm.nih.gov/pubmed/15245670",
    "http://www.ncbi.nlm.nih.gov/pubmed/17954092",
    "http://www.ncbi.nlm.nih.gov/pubmed/11126742",
    "http://www.ncbi.nlm.nih.gov/pubmed/18082353",
    "http://www.ncbi.nlm.nih.gov/pubmed/16437936",
    "http://www.ncbi.nlm.nih.gov/pubmed/17470686",
    "http://www.ncbi.nlm.nih.gov/pubmed/14753595",
    "http://www.ncbi.nlm.nih.gov/pubmed/19829995",
    "http://www.ncbi.nlm.nih.gov/pubmed/19343179",
    "http://www.ncbi.nlm.nih.gov/pubmed/16821517",
    "http://www.ncbi.nlm.nih.gov/pubmed/17643218",
    "http://www.ncbi.nlm.nih.gov/pubmed/18180842",
    "http://www.ncbi.nlm.nih.gov/pubmed/15993051",
    "http://www.ncbi.nlm.nih.gov/pubmed/24325620"
  ],
  "snippets": [
    {
      "text": "Traditionally, the treatment of choice for primary disease is surgical resection",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24325620",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "no single surgeon or institution gets extensive exposure to these patients so appropriate decision-making is difficult, particularly since the introduction of the tyrosine kinase inhibitor imatinib, which has become an important additional management tool",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24325620",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Surgery aiming at an R0 resection remains the mainstay of treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24325620",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The treatment of choice for GIST is surgical resection",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22678007",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Extra luminal colonic gastrointestinal stromal tumors are very rare and can present as mass abdomen. Resection is the treatment of choice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19829995",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Surgery remains the only curative treatment for gastrointestinal stromal tumour (GIST).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19343179",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "When they are localized, the treatment of choice is surgical excision, but advanced tumors have a limited response to chemo or radiotherapy. Imatinib (STI571 or Glivec) is a selective inhibitor or tyrosine kinase proteins that has been used successfully in the treatment of advanced GIST.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18180842",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Therefore Imatinib can be a therapeutic alternative in patients with metastatic GIST.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18180842",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The surgical resection is a treatment of choice for gastrointestinal stromal tumors. It has been shown that adequate surgical resection correlates with high 5-years survival rates for patients with gastric GIST.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19097381",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Approximately 80% of patients with metastatic GIST benefit from imatinib, although acquired resistance to the agent may develop. For patients with primary GIST, surgery remains the treatment of choice, and whether outcome is improved by adjuvant imatinib is currently under broad investigation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16136600",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "combination of imatinib therapy and surgery also may be effective in a subset of patients with metastatic or unresectable primary GIST",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16136600",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}